DOASENSE - Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
 NEWS FLASH:
      • 2024-09: Recent guideline from the British Society of Haematology on the measurement of direct oral anti-coagulants lists the DOASENSE point-of-care test [read here]

      • 2024-07: New series of interviews with users of the DOASENSE test launched. Find out more about their experiences and use cases. [watch videos]

      • 2024-04: DOASENSE test included in new Guideline published by the European Society of Anaesthesiology and Intensive Care [read more]

      • 2024-02: Expert consensus published on algorithm for rapid exclusion of clinically relevant plasma levels of DOACs using the DOAC Dipstick  [download here]

      • 2024-01: Updated version of White Paper available with a summary of key publications on the DOASENSE test suite [download here]

      • 2023-11: DOASENSE becoming a standard of care in Italy and Estonia [read more]

      • 2023-02: New study published in STROKE, provides evidence for using the DOAC Dipstick test to identify patients for prompt thrombolysis [read more]

    READ ALL NEWS [HERE]
    When every minute counts … fast DOAC testing matters.

    DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel and quick point-of-care urine tests

    The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.


    DOASENSE offers products for specific testing for DOACs in urine

    Tests which are easy to use and easy to interpret, reproducible, and patient friendly

    Learn from users of the DOASENSE test
    about their personal experiences and use cases:

    Listen to what other opinion leaders think about DOASENSE's solutions:
    Typical clinical scenarios where testing for specific DOACs can be of value

      • Stroke (e.g. before thrombolytic therapy)
      • Trauma
      • Emergency procedures
      • Evaluating for venous thromboembolism
      • Spontaneous hemorrhage
      • General surgery or invasive procedures
      • Other situations where medication history may not available

    In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure

    Accelerate your clinical decisions and treat patients earlier!


    Please note that our products are for health care professional use only!
    Divider
    NOTE: DOASENSE(TM) products may not be available or approved in your country.


    Copyright (c) 2016-2024 DOASENSE GmbH. All rights reserved.
    Back to content